Three-month follow-up of Pulmonary Embolism in patients with COVID-19

Coronavirus disease 2019 (COVID-19) infection has been notable for the occurrence of pulmonary venous thrombosis, also known as immunothrombosis, in addition to classical pulmonary embolism [1]. The pathophysiology underpinning this appears more platelet-dependent and related to viral-mediated endothelial inflammation, in addition to hypercoagulability [2]. To date, treatment of confirmed pulmonary embolism (PE) has followed established (pre-COVID) venous thromboembolism (VTE) guidelines [3] but it is not known whether the subsequent clinical behaviour of COVID-associated VTE differs from outcomes reported prior to the COVID-19 pandemic.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research